VIRILON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Virilon, and when can generic versions of Virilon launch?
Virilon is a drug marketed by Chartwell and is included in one NDA.
The generic ingredient in VIRILON is methyltestosterone. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methyltestosterone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Virilon
A generic version of VIRILON was approved as methyltestosterone by IMPAX LABS on December 31st, 1969.
Summary for VIRILON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 57 |
Clinical Trials: | 1 |
Patent Applications: | 4,413 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VIRILON at DailyMed |
Recent Clinical Trials for VIRILON
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Emory University | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for VIRILON
US Patents and Regulatory Information for VIRILON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chartwell | VIRILON | methyltestosterone | CAPSULE;ORAL | 087750-001 | Nov 24, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |